Sign up to save your podcasts
Or
Share Théa Acquires ProQR’s LCA10 and USH2A Treatment Programs, Plans to Continue Clinical Development
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Théa Acquires ProQR’s LCA10 and USH2A Treatment Programs, Plans to Continue Clinical Development
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
View all episodes
By Foundation Fighting Blindness
4.9
2525 ratings
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
More shows like Foundation Fighting Blindness
View all
Fresh Air
38,592 Listeners
The Joe Rogan Experience
229,308 Listeners
Planet Money
30,855 Listeners
Making Sense with Sam Harris
26,323 Listeners
Pivot
9,589 Listeners
Science Friday
6,439 Listeners
The Daily
112,882 Listeners
The Jordan Harbinger Show
12,020 Listeners
The Journal.
6,086 Listeners
The Prof G Pod with Scott Galloway
5,553 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,220 Listeners
SmartLess
58,904 Listeners
The Bible in a Year (with Fr. Mike Schmitz)
62,640 Listeners
Huberman Lab
29,328 Listeners
The Ezra Klein Show
16,223 Listeners